NCT07099157

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.

Detailed description

A randomized controlled trial enrolling 140 participants from 5 centers in China. Patients receive either Brivudine (125mg/day) or Famciclovir (dose-adjusted by creatinine clearance) for 7 days. Follow-ups occur at Day 3, Day 7, Day 14, Day 30, Day 90. Primary endpoint: Numeric Pain Rating Scale (NPRS) at Day 30; secondary endpoints: NPRS at other timepoints, lesion healing time, Postherpetic Neuralgia (PHN) rate, and adverse events.

Conditions

• Herpes Zoster

Interventions

Type	Name	Description
DRUG	Brivudine	brivudine 125 mg per dose, once daily, 7 days
DRUG	Famciclovir	orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days

Timeline

• Start date: 2025-08-25
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2025-08-01
• Last updated: 2026-01-02

Locations

4 sites across 1 country: China